Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,607 Cr
Revenue (TTM)
₹559 Cr
Net Profit (TTM)
₹-8 Cr
ROE
-0.2 %
ROCE
0.6 %
P/E Ratio
--
P/B Ratio
3.1
Industry P/E
36.53
EV/EBITDA
-480.3
Div. Yield
0 %
Debt to Equity
0
Book Value
₹136.3
EPS
₹-216.5
Face value
1
Shares outstanding
61,250,746
CFO
₹26.70 Cr
EBITDA
₹125.01 Cr
Net Profit
₹483.76 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Panacea Biotec
| 1.8 | -19.9 | -1.3 | 222.4 | 49.4 | 15.2 | 13.0 |
|
BSE Healthcare
| -4.6 | 0.9 | 5.1 | 17.0 | 27.1 | 21.6 | 10.3 |
|
BSE Small Cap
| -4.4 | 1.8 | 13.8 | 1.9 | 29.5 | 33.7 | 17.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Panacea Biotec
| 142.3 | 18.2 | -28.5 | -16.5 | 84.2 | -17.9 | -33.8 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Panacea Biotec
|
426.1 | 2,606.5 | 559.1 | -8.7 | -10.9 | -159 | -- | 3.1 |
| 727.9 | 2,093.1 | 451.8 | 50.8 | 11.4 | 16.3 | 41.2 | 6.4 | |
| 455.0 | 7,411.9 | 2,108.1 | 266.8 | 12.5 | 11.7 | 27.8 | 3.2 | |
| 355.8 | 3,569.4 | 819.8 | 69.7 | 13.9 | 11.9 | 51.2 | 5.9 | |
| 5,907.0 | 9,778.8 | 1,218.1 | 251.2 | 28.1 | -- | 38.9 | 18.2 | |
| 880.5 | 8,649.6 | 1,286.4 | 79.6 | 15.9 | 4.7 | 110.5 | 3.6 | |
| 826.8 | 7,614.5 | 4,632.7 | 358.2 | 14.8 | 15 | 2.1 | 3.0 | |
| 681.8 | 5,484.9 | 696.5 | 188.0 | 34.5 | 19.8 | 29.2 | 5.5 | |
| 19.2 | 1,802.0 | 466.0 | 49.4 | 10.7 | 15.1 | 36.5 | 5.3 | |
| 884.4 | 1,853.2 | 759.9 | 61.0 | 8.7 | 12.5 | 30.4 | 3.7 |
1 min read•By Danish Khanna
Companies that have Attracted Institutions
1 min read•By Vikas Vardhan
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates... through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosis management, orthopedics, pain management, and fever; and betacoronavirus, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, hepatitis A, and varicella vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc for the manufacture and supply of Azacitidine injection; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India. Read more
Incorporated
1984
Chairman
Rajesh Jain
Managing Director
Rajesh Jain
Group
Soshil Kumar Jain
Headquarters
Lalru, Punjab
Website
Looking for more details about Panacea Biotec Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Panacea Biotec Ltd stood at ₹ 1,290 Cr as on 31-Mar-25
The share price of Panacea Biotec Ltd is ₹426.05 (NSE) and ₹425.55 (BSE) as of 20-Jun-2025 IST. Panacea Biotec Ltd has given a return of 49.37% in the last 3 years.
Panacea Biotec Ltd has a market capitalisation of ₹ 2,607 Cr as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Panacea Biotec Ltd is 3.12 times as on 20-Jun-2025, a 41% discount to its peers’ median range of 5.27 times.
Since, TTM earnings of Panacea Biotec Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Panacea Biotec Ltd and enter the required number of quantities and click on buy to purchase the shares of Panacea Biotec Ltd.
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosis management, orthopedics, pain management, and fever; and betacoronavirus, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, hepatitis A, and varicella vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc for the manufacture and supply of Azacitidine injection; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
The prominent promoters of Panacea Biotec Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Dr. Rajesh Jain |
49.33%
|
|
Mr. Sandeep Jain |
15.27%
|
|
Mrs. Nirmala Jain |
4.1%
|
|
First Lucre Partnership Co. |
3.68%
|
The chairman of the company is Rajesh Jain, and the managing director is Rajesh Jain.
There is no promoter pledging in Panacea Biotec Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,779
|
|
|
8,650
|
|
|
7,614
|
|
|
7,412
|
|
|
5,485
|
|
|
3,569
|
|
|
2,093
|
|
|
1,853
|
|
|
1,802
|
| Panacea Biotec Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-159
|
|
Operating margin(%)
|
-10.86
|
|
Net Margin(%)
|
-1.5
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Panacea Biotec Ltd was ₹-8 Cr.
₹0.75
(
